| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 20.27 | 817.2% |
| Total Income | 20.27 | 817.2% |
| Expenditure | 10.09 | 13.3% |
| PBT | 8.72 | 182.3% |
| Net Profit | -7.02 | 32.9% |
| OPM | 50.23% | |
| NPM | -34.60% | |
| EPS | -13.60 | 18.6% |
Jaguar Health Reports Q1 2026 Revenue Up 816% YoY
21 May 2026 · 21 May, 2:12 am
Summary
Jaguar Health reported a significant increase in net revenue for Q1 2026, up 816% compared to the same period in 2025, primarily due to licensing agreements. The company recognized $19.068 million in license and grant revenue. Prescription product revenue decreased by 45% year-over-year. Despite the revenue growth, the net loss attributable to common shareholders decreased by $3.4 million, and the company is focusing on crofelemer development for rare-disease intestinal failure indications.
Key Highlights
- 1
Net revenue increased 816% in Q1 2026 compared to Q1 2025, driven by the license of U.S. commercial rights for Mytesi® and Canalevia®-CA1.
- 2
License and grant revenue reached $19.068 million in Q1 2026, compared to $43 in Q1 2025.
- 3
Prescription product revenue was approximately $1.2 million in Q1 2026, a decrease of 45% compared to $2.2 million in Q1 2025.
- 4
Income from operations increased by $19.6 million, reaching $10.2 million in Q1 2026 from a loss of $9.4 million in Q1 2025.
- 5
Net loss attributable to common shareholders decreased by approximately $3.4 million, from a loss of $10.5 million in Q1 2025 to a loss of $7.1 million in Q1 2026.
- 6
Non-GAAP Recurring EBITDA improved to a net loss of $5.06 million in Q1 2026, compared to a net loss of $9.739 million in Q1 2025.
Informational and educational content only. Not investment advice.